Results Published from Trial of Siponimod in Secondary Progressive MS

The Lancet recently published an article demonstrating the efficacy of a new MS medication, Siponimod, in secondary progressive MS patients. Siponimod is very similar to a currently available medication, called fingolimod or gilenya, but may have a better safety profile. The results of the study were modest and research on this drug is ongoing. 

 

To read more about the published article please click here

News Date : 
Thursday, April 12, 2018 (All day)

IMSMP

Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.

Eventbrite - Tisch MS Research Center 21st Annual MS Patient Symposium